Peter Marks, who’s responsible for the FDA’s oversight of cell and gene therapies, expects regulators around the world will be better at collaborating on gene …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Dive Brief: The Food and Drug Administration has proposed changing antigen, antibody and nucleic acid-based hepatitis B virus (HBV) assays to a lower-risk classification. Currently, the
Griffith University researchers are on the brink of a technological breakthrough in vaccine development with a possible new vaccine modality.
Genetic studies of diseases map segments of the genome driving disease. But to understand how those changes contribute to disease progression, it is important to